Eglin Pharmaceuticals Awarded National High-Tech Enterprise Certification

Recently, Shenzhen Evergreen Therapeutics (hereinafter referred to as "Evergreen Therapeutics") was awarded the "National High-tech Enterprise" certification by the Shenzhen Industry and Information Technology Bureau, Shenzhen Finance Bureau, and the Shenzhen Taxation Bureau of the State Administration of Taxation.

National High-Tech Enterprise Certification is one of the most authoritative honors in China's scientific and technological innovation field. The certification process follows a rigorous and comprehensive standard system, covering multi-dimensional key indicators such as the quantity and quality of core independent intellectual property rights, transformation of scientific and technological achievements, the scientific nature and standardization of research and development organizations, as well as the overall growth and development potential of the enterprise. This certification not only represents a high-level summary of the enterprise’s past innovative achievements but also reflects deep expectations for its continued leadership in the industry in the future.

Since its establishment, Evergreen Therapeutics has always adhered to the principle of addressing urgent clinical needs, focusing on the development of first-in-class drugs globally. It was among the first in China to apply AI technology to clinical research and development, relying on its self-developed AI platform to create a more efficient R&D model and accelerate the translation of drugs from the laboratory to clinical practice. The company places great emphasis on talent team building, gathering top talents from around the world, and has formed a high-quality, multi-disciplinary R&D team covering everything from early drug discovery to late-stage clinical research, providing solid support for technological innovation. Currently, among the proprietary pipelines empowered by AI technology at Evergreen Therapeutics, six have received IND approval from the U.S. FDA, with over 50 patent applications filed, covering major pharmaceutical markets worldwide including China, the U.S., Europe, and Japan, fully demonstrating the company's strong execution capabilities in transforming scientific research achievements and implementing a global layout.

This recognition highly affirms Evergreen Therapeutics' scientific research capabilities and continuous innovation. In the future, Evergreen Therapeutics will continue to uphold the "innovation-driven" philosophy, focus on the development of Me-Only innovative drugs, promote the advancement of AI clinical technologies, and accelerate the internationalization of innovative drugs, constantly strengthening its core competitiveness to bring more treatment options to patients worldwide.